Protagonist Therapeutics (NASDAQ: PTGX) and EXACT Sciences (NASDAQ:EXAS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

39.7% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 82.4% of EXACT Sciences shares are held by institutional investors. 15.5% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 4.0% of EXACT Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Protagonist Therapeutics and EXACT Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics 0 0 2 0 3.00
EXACT Sciences 0 5 9 0 2.64

Protagonist Therapeutics currently has a consensus target price of $39.50, indicating a potential upside of 100.71%. EXACT Sciences has a consensus target price of $51.46, indicating a potential upside of 1.93%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than EXACT Sciences.

Profitability

This table compares Protagonist Therapeutics and EXACT Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics N/A -64.21% -50.51%
EXACT Sciences -60.71% -30.32% -27.37%

Earnings and Valuation

This table compares Protagonist Therapeutics and EXACT Sciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics N/A N/A -$37.17 million ($2.78) -7.08
EXACT Sciences $99.38 million 60.83 -$167.21 million ($1.15) -43.90

Protagonist Therapeutics has higher earnings, but lower revenue than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.